Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | SLC5A7 | Q9GZV3 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31267275 | 1.00 | NPC1 (0.56) | NPC1RAB9ALMNAPOLBGABRA5 | |
| SCHEMBL411124 | 0.87 | NPC1 (0.49) | NPC1RAB9ALMNAPOLBGABRA5 | |
| SCHEMBL412268 | 0.85 | RHOC (0.41) | NPC1RAB9APOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL410643 | 0.85 | CNR2 (0.43) | NPC1RAB9ALMNAPOLBSMN1; SMN2 | |
| SCHEMBL412341 | 0.85 | NPC1 (0.53) | NPC1RAB9ALMNAPOLBGABRA5 | |
| SCHEMBL16927382 | 0.83 | RAB9A (0.46) | NPC1RAB9ALMNAPOLBGABRA5 | |
| SCHEMBL412251 | 0.81 | NPC1 (0.53) | NPC1RAB9ALMNAPOLBGABRA5 | |
| SCHEMBL438387 | 0.80 | MAPT (0.45) | GABRA5TP53MAPTCTSA | |
| SCHEMBL412285 | 0.75 | POLB (0.41) | NPC1RAB9ALMNAPOLBGABRA5 | |
| SCHEMBL411012 | 0.74 | MRGPRX4 (0.52) | NPC1RAB9ASMN1; SMN2L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | claimed |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200085810-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN-LA ROCHE INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020021097-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-30 | — | — | WO | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | NPC1 16/4885RAB9A 840/4885LMNA 886/4885 |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, PLAAT2 | NPC1 23/4885RAB9A 648/4885LMNA 1133/4885 |
| US-20200085810-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, PLAAT2 | NPC1 23/4885RAB9A 648/4885LMNA 1133/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | NPC1 16/4885RAB9A 840/4885LMNA 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.